Workflow
23andMe (ME)
icon
Search documents
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
GlobeNewswire News Room· 2024-06-28 11:00
Core Insights - 23andMe and Nightingale Health have announced a strategic collaboration to pilot a blood metabolomics panel with 23andMe members, aiming to enhance preventive health measures and risk prediction [1][5][6] Group 1: Collaboration Details - The pilot will utilize Nightingale's Remote Health Check, which measures various biomarkers from a single blood sample, including cholesterols and fatty acids, to guide lifestyle interventions [2][5] - Up to 5,000 23andMe+ Premium and Total Health members will receive blood testing at no cost, allowing the companies to gather customer feedback on the testing process and data utility [4][5] Group 2: Technological Integration - The collaboration aims to combine the strengths of both companies, enhancing 23andMe's existing health services with Nightingale's advanced biomarker testing technology [6] - This partnership is expected to provide a comprehensive health assessment and continuous tracking of health progress for customers [5][6] Group 3: Company Vision - Both companies share a vision of empowering individuals to identify health risks and prevent diseases through proactive testing and lifestyle changes [5][6] - The collaboration is seen as a significant step in Nightingale Health's strategy to access the consumer health market [6]
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Investor Place· 2024-06-11 10:00
Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable. However, despite their low prices, these stocks are often the riskiest to own. Many are still in the process of establishing themselves in their respective markets or lack a solid foundation for significant growth. That said, there are exceptions. These three penny stocks are loaded with growth potential and have exciting developments c ...
UK and Canada privacy watchdogs investigating 23andMe data breach
TechCrunch· 2024-06-10 15:11
On Monday, the U.K,'s Information Commissioner's Office (ICO) and the Office of the Privacy Commissioner of Canada (OPC) announced their investigation into the genetic testing company, saying the organizations will leverage "the combined resources and expertise of their two offices." "This data breach had an international impact, and we look forward to collaborating with our Canadian counterparts to ensure the personal information of people in the U.K. is protected," said Edwards. Hackers broke into around ...
23andMe Launches New Genetic Report on Bipolar Disorder
Newsfilter· 2024-06-05 11:00
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at higher likelihood for being diagnosed with the condition. Bipolar disorder is a mental health condition that can cause extreme and unusual shifts in mood, energy, behavior and activity, ranging from highs (mania) to ...
Why 23andMe Stock Tumbled 10% on Tuesday
The Motley Fool· 2024-06-04 16:48
Is altruism a good idea for an unprofitable capitalistic enterprise? Genetic database builder 23andMe (ME -11.45%) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal Cancer Alliance "to help advance research on colorectal cancer in the Black/African American community." Now, why might investors consider this bad news for 23andMe stock? Non-profit plus ...
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
Newsfilter· 2024-06-04 11:00
SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaboration to help advance research on colorectal cancer in the Black/African American community. The Genetic Insights into Colorectal Cancer in the Black Community Study is part of 23andMe's continued efforts to raise aware ...
23andMe (ME) - 2024 Q4 - Annual Report
2024-05-30 20:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ______________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM___________ TO___________ Commission File Number 001-39587 ___________________________________________ ...
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
globenewswire.com· 2024-05-29 12:00
The LRRK2 variant is strongly associated with symptoms of Parkinson's disease (PD) that are different from non-variant carriers with the disease The study revealed novel findings of genetic "hotspots" in people from Mexico, Cuba, Puerto Rico, and Brazil, where the founder variant has sprung up in other communities 23andMe has the largest LRRK2 G2019S research cohort, and launched the Parkinson's Impact Project (PIP) in 2018 to better understand which carriers are at greater risk of developing Parkinson's di ...
23andMe (ME) - 2024 Q4 - Annual Results
2024-05-23 20:07
EXHIBIT 99.1 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results SOUTH SAN FRANCISCO, Calif., May 23, 2024 -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments "The Company had a productive fourth quarter and solid end to the year, continuing to add value for members of 23andMe+ and advan ...
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
globenewswire.com· 2024-05-23 20:05
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024. Key Results and Recent Developments "The Company had a productive fourth quarter and solid end to the year, continuing to add value for members of 23andMe+ and advancing our clinical stage assets," said Anne Wojcicki, Co-Founder & CEO o ...